Asterias Biotherapeutics, Inc. AST 深 滬
已收盤 03-08 16:00:00 美东时间
0.945
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.945
- 總市值 0
- 52周最高 1.95
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.51
- 委 比 0.00%
- 總股本 0
- 歷史最高 15.10
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
09-05 21:09
ASTRAUX推出三款原创设计产品
在柏林全球发布会上，科技品牌ASTRAUX推出了三款原创设计产品。ASTRAUX迷你电动车，设计紧凑时尚，采用汽车级车身结构、全景玻璃天窗，拥有360°无死角视...
09-05 17:08
Q-linea Expands ASTar Clinical Evaluations to GCC Region
Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea AB has announced the ...
09-05 16:32
What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.
09-05 02:52
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.
09-05 02:36
Sanofi’s Amlitelimab Shows Promising Results in Atopic Dermatitis Study
Sanofi ( ($SNY) ) has issued an update. On September 4, 2025, Sanofi announced ...
09-05 01:17
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.
09-04 21:21
赛诺菲(SNY.US)全球首创OX40L单抗III期研究成功
赛诺菲(SNY.US)宣布Amlitelimab治疗特应性皮炎的III期COAST 1研究达到了所有主要终点和次要终点。
09-04 21:16
美股机会日报 | 或利好9月降息！美国8月“小非农”人数低于预期；英伟达拟向中国市场推出Blackwell架构芯片
或利好9月降息！美国8月“小非农”人数低于预期；英伟达拟向中国市场推出Blackwell架构芯片；瑞银称美国经济已滑入疲软区域>>
09-04 20:21
库兹马惊喜助阵！NBA 3X北部大区赛沈阳燃情落幕
来源：环球网 8月31日晚，经过两天激战，NBA 3X北部大区赛在NBA HOOP PARK沈阳皇姑馆落下帷幕，中源牧业（公开组）、烟台友缘（精英组）、魏桥创...
09-02 11:14
